Literature DB >> 9829532

Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain.

A Ghodsi1, C Stein, T Derksen, G Yang, R D Anderson, B L Davidson.   

Abstract

Mucopolysaccharidosis type VII (MPS VII), caused by beta-glucuronidase deficiency, is a classic lysosomal storage disease. In the central nervous system (CNS), there is widespread pathology with distention of vacuoles in neurons and glia. An approach to therapy for MPS VII would require extensive delivery of enzyme to the CNS and subsequent uptake by the affected cells. In this study we show that intrastriatal injection of recombinant adenovirus encoding beta-glucuronidase (Ad betagluc) to MPS VII or wild-type mice results in focal, intense beta-glucuronidase mRNA expression near the injection site. Further, histochemical staining for enzyme activity showed that beta-glucuronidase activity extended well beyond transduced cells. Activity was detected throughout the ipsilateral striatum as well as in the corpus callosum, ventricles, and bilateral neocortex. Similarly, after injection into the right lateral ventricle or cisterna magna, enzyme activity was present in the ependymal cells of the ventricles, in the subarachnoid spaces, and also in the underlying cortex (150-500 microm from ependyma). The distribution of enzyme was most extensive 21 days after gene transfer to normal mouse brain, with more than 50% of the hemisphere positive for beta-glucuronidase activity. Eighty-four days after adenovirus injection a substantial level of enzyme expression remained (>40% of hemisphere positive for beta-glucuronidase activity). Histological sections from striatum of beta-glucuronidase-deficient mice injected with Ad betagluc showed a marked reduction in the number of distended vacuoles in both neurons and glia, as compared with uninjected striatum. Importantly, correction was noted in both hemispheres. Our finding that a relatively small number of transduced cells produce enzyme that reaches a large proportion of the CNS has favorable implications in developing direct gene transfer therapies for lysosomal storage disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829532     DOI: 10.1089/hum.1998.9.16-2331

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  17 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 2.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

3.  Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.

Authors:  W S Sly; C Vogler; J H Grubb; M Zhou; J Jiang; X Y Zhou; S Tomatsu; Y Bi; E M Snella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

4.  Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.

Authors:  Shunji Tomatsu; Koji O Orii; Carole Vogler; Jeffrey H Grubb; Elizabeth M Snella; Monica Gutierrez; Tatiana Dieter; Christopher C Holden; Kazuko Sukegawa; Tadao Orii; Naomi Kondo; William S Sly
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

Review 5.  Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?

Authors:  Jacqueline A Hawkins-Salsbury; Adarsh S Reddy; Mark S Sands
Journal:  Hum Mol Genet       Date:  2011-03-19       Impact factor: 6.150

6.  Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors.

Authors:  Andrew I Brooks; Colleen S Stein; Stephanie M Hughes; Jason Heth; Paul M McCray; Sybille L Sauter; Julie C Johnston; Deborah A Cory-Slechta; Howard J Federoff; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 7.  Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2011-05-17       Impact factor: 4.982

8.  Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium.

Authors:  H Xia; B Anderson; Q Mao; B L Davidson
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C.

Authors:  M Chillon; A Bosch; J Zabner; L Law; D Armentano; M J Welsh; B L Davidson
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 10.  CNS-directed gene therapy for lysosomal storage diseases.

Authors:  Mark S Sands; Mark E Haskins
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.